Product Description
Sanofi is developing Imojev as a treatment for Japanese Encephalitis. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT01900444)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | India | Indonesia | Italy | Korea | Latvia | Malaysia | Mexico | New Zealand | Norway | Pakistan | Philippines | Portugal | Russia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: Europe
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Finland, France, Germany, Mexico, Spain
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Yellow Fever
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2020-005566-33 |
2020-005566-33 | P2 |
Active, not recruiting |
Yellow Fever |
2026-06-07 |
2022-03-13 |
Treatments |
|
2022-502047-35-00 |
VYF03 | P2 |
Active, not recruiting |
Yellow Fever |
2027-01-07 |
2025-05-02 |
Treatments |
|
NCT07103148 |
VYF04 | P3 |
Recruiting |
Yellow Fever |
2026-08-08 |
22% |
2025-08-06 |